We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ovarian Cell Hormone Predicts Onset of Menopause

By LabMedica International staff writers
Posted on 06 Jul 2010
Levels of a hormone, produced by cells in the ovary, can be used to predict when a woman's menopause will begin.

A hormonal blood test can accurately predict at what age a woman's reproductive status will change. Different quantities of the hormone in the blood can be used to assess when the permanent cessation of ovarian function will occur.

Scientists at the Shahid Beheshti University of Medical Sciences (Tehran, Iran) have measured the anti-Mullerian Hormone (AMH) concentration in women enrolled in a study since 1998. AMH controls the development of follicles in the ovaries, from which oocytes (eggs) develop and it has been suggested that AMH could be used for measuring ovarian function. Blood samples were taken at three yearly intervals, and they also collected information on the women's socioeconomic background and reproductive histories.

The results from the study enabled the scientists to make a more realistic assessment of women's reproductive status many years before they reach menopause. For example, if a 20-year-old woman has a concentration of serum AMH of 2.8 ng/mL they estimate that she will become menopausal between 35 to 38 years old. The statistical model used to correlate AMH levels at different ages could predict if women were likely to have an early menopause (before the age of 45). They found that AMH levels of 4.1 ng/mL or less predicted early menopause in 20-year-olds, AMH levels of 3.3 ng/mL predicted it in 25-year-olds, and AMH levels of 2.4 ng/mL predicted it in 30-year-olds. In contrast, AMH levels of at least 4.5 ng/mL at the age of 20, 3.8 ngl/mL at 25 and 2.9 ng/mL at 30 all predicted an age at menopause of over 50 years old. The results of the study were presented at the annual meeting of European Society of Human Reproduction and Embryology held in June, 2010 in Rome, Italy.

The estimates of ages at menopause based on AMH levels are of sufficient validity to guide medical practitioners in their day-to-day practice, so that they can help women with their family planning.

Related Links:
European Society of Human Reproduction and Embryology



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.